| Literature DB >> 26774106 |
Sedona Sweeney1, Anna Vassall1, Nicola Foster2, Victoria Simms1, Patrick Ilboudo3, Godfather Kimaro4, Don Mudzengi5, Lorna Guinness1.
Abstract
Out-of-pocket spending is increasingly recognized as an important barrier to accessing health care, particularly in low-income and middle-income countries (LMICs) where a large portion of health expenditure comes from out-of-pocket payments. Emerging universal healthcare policies prioritize reduction of poverty impact such as catastrophic and impoverishing healthcare expenditure. Poverty impact is therefore increasingly evaluated alongside and within economic evaluations to estimate the impact of specific health interventions on poverty. However, data collection for these metrics can be challenging in intervention-based contexts in LMICs because of study design and practical limitations. Using a set of case studies, this letter identifies methodological challenges in collecting patient cost data in LMIC contexts. These components are presented in a framework to encourage researchers to consider the implications of differing approaches in data collection and to report their approach in a standardized and transparent way.Entities:
Keywords: catastrophic expenditures; data collection methods; economic evaluation; out-of-pocket payments; poverty
Mesh:
Year: 2016 PMID: 26774106 PMCID: PMC5066802 DOI: 10.1002/hec.3304
Source DB: PubMed Journal: Health Econ ISSN: 1057-9230 Impact factor: 3.046
Case study characteristics
| MERGE (Kufa | XTEND (Foster | ECONPOP (Ilboudo | REMSTART (Mfinanga | |
|---|---|---|---|---|
| Country | South Africa | South Africa | Burkina Faso | Zambia and Tanzania |
| Aim of study | Implementation and evaluation of an optimized model for scaling up TB/HIV integration at primary care clinics | Evaluation of the implementation of a new TB diagnostic, XPert MTB/RIF | Multidisciplinary study to estimate costs and consequences of abortion | Trial assessing a complex intervention to reduce mortality in ART‐naive patients beginning ART |
| Study design | Cluster‐randomized trial | Cluster‐randomized trial | Cross‐sectional survey | Individually randomized control trial |
| Time frame | Cross‐sectional | Cohort | Cross‐sectional | Longitudinal |
| Sampling for cost data | Convenience sample at study facilities | Random subsample of study‐enrolled patients | Convenience sample at study facilities | All participants at study clinics. Clinics chosen for convenience |
| Location of interview | Facility | Facility | Facility | Facility |
| Sample size | 459 for costs | 351 for costs | 304 for economic study | 1375 for costs |
| 3,478 total for trial | 4,656 total for trial | 1,999 total for trial | ||
| Subgroups ( | TB only (41) | No TB treatment (302) | Induced (37) | Intervention (684) |
| TB/HIV (119) | Control (691) | |||
| HIV only (299) | Started on treatment (49) | Spontaneous (267) | Tanzania (870) | |
| Zambia (505) | ||||
| OOP cost ingredients | Transport for individual and companion, medicines and consumables, diagnostics, consultation fees, special food/supplements, and inpatient accommodation | Transport for individual and companion, medicines and consumables, diagnostics, consultation fees, special food/supplements, and inpatient accommodation | Medicines and consumables, consultation fees, ultrasound, informal payments, pre‐referral costs, and hospitalization | Transport and ‘other’ costs |
| Recall period (costs) | The last visit to each provider (variable; max 5 months) | The last month | ~1 day (interviewed on discharge) | 1 day (cost of visit only) |
| Household/individual costs | Individual and guardian / caregiver | Individual and guardian / caregiver | Individual | Individual and guardian / caregiver |
| Average length of interview (min) | ~60 | ~45 | ~20 | ~25 |
| Diary/recall | Recall | Recall | Recall | Recall |
| Indirect cost measurement | Human capital approach and income loss | Income loss | None | Human capital approach |
| Additional health services costed | Pharmacy, GP, outpatient hospital, inpatient hospital, and traditional healer | Pharmacy, GP, outpatient hospital, inpatient hospital, and traditional healer | None | None |
| Source of income data | Annual individual income before and after diagnosis | Annual individual income before and after diagnosis | None (GDP per capita used as proxy) | Individual income in last month |
| Interviewers used | Research assistants | Nurses and research assistants | Trained female interviewers | Trained field workers |
| Medium of recording | Paper survey | Electronic survey | Paper survey | Paper survey |
| Average cost (95% CI) | Monthly OOP expenditures: $1.02 ($0.44 ‐ $1.60)Monthly travel costs: $2.31 ($1.75 – $2.87)Monthly food costs: $10.93 ($9.44 – $12.41)Monthly indirect costs: $15.67 ($11.88 – $19.46)Monthly income loss: $25.83 ($16.33 – $35.33)Monthly guardian costs: $6.43 ($4.59 – $8.26)Monthly carer costs: $4.63 ($1.60 – $7.65) | Total OOP expenditures: $111.83Total loan interest: $43.32Total income loss: $54.82Total guardian costs: $32.11Total carer costs: $81.99Total episode cost: $324.07 | Total OOP expenditures: $52.80 ($47.36–$58.24) | OOP expenditures for one visit to study facility: $1.96 ($1.80–$2.13) |
| Average annual income (95% CI) | $2,565 ($2,225 – $2,905) | $1,237 ($1,001 – $1,474) | Not measured (GDP per capita used as proxy) | Tanzania: $244 ($212 – 276) |
| Zambia: $219 ($199–239) | ||||
| National poverty line (USD) | $773 | $773 | $184 | Tanzania: $234 |
| Zambia: $266 | ||||
| GDP per capita (USD) | $6,618 | $6,618 | $531 | Tanzania: $695 |
| Zambia: $1,845 | ||||
| Frequency of catastrophic expenditure at 20% threshold (95% CI) | 40% (36–45%) | 59% (54–65%) | 10% (6–14%) | 4% (3–5%) |
| Minimum sample size required to estimate frequency of catastrophic expenditure with 95% CI | Error margin 5%: 2,282 | Error margin 5%: 1,057 | Error margin 5%: 13,689 | Error margin 5%: 36,504 |
| Error margin 10%: 570 | Error margin 10%: 264 | Error margin 10%: 3,422 | Error margin 10%: 9,126 | |
| Error margin 15%: 254 | Error margin 15%: 117 | Error margin 15%: 1,521 | Error margin 15%: 4,056 |
ART, antiretroviral therapy; OOP, out‐of‐pocket; GDP, gross domestic product; GP, general practitioner.
Framework for planning/reporting data collection
| Study planning component | Items for consideration |
|---|---|
| Comprehensiveness of survey design | • Which OOP expenditures are included? |
| • What is the level of disaggregation in cost ingredients and how long is the survey? | |
| • Are any context‐specific variables included? | |
| • How is income measured, and whose income is collected (i.e., personal or household income)? | |
| Time frame and recall | • What is the recall period for the survey? Is it appropriate to capture all economic outcomes? |
| • What is the complexity of the disease pathway? Is there resulting potential for recall bias? | |
| • Is there potential for cost truncation in the context of chronic disease and/or future complications? | |
| • Are coping strategies used to estimate the long‐term economic impact of health spending? | |
| • What is the recall period for income measurement (i.e., current vs. pre‐diagnosis)? | |
| Sample size and representativeness | • What is the confidence interval and margin of error deemed acceptable? |
| • If estimating impoverishing expenditures, what is the distribution of pre‐diagnosis income relative to the poverty line? | |
| • Are any adjustments to sample size required to account for clustering or non‐response? | |
| Data sources and survey administration | • Is a cost diary or recall used to capture expenditures? |
| • Are data supplemented with any additional data sources, such as retrospective records review or GIS data? | |
| • Where is the interview conducted and by whom? | |
| • What is the medium of collecting and recording data (i.e., electronic, paper, or telephone surveys)? |
GIS, geographic information system.
Figure 1Potential advantages and limitations of alternative approaches in data collection